pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
GILEAD · news · pharmadog
← back to GILEAD
News mentioning GILEAD
190
stories
Sep 24, 26
STAT+: FDA commissioner nominee Heidi Overton keeps opinions to herself in Senate hearing
stat
Sep 24, 26
The FDA’s Overton era, and dispatches from Shanghai
stat
Sep 24, 26
STAT+: Why Gilead can’t stop talking about its ambitions in immunology
stat
Sep 18, 26
Electra lights up with $350M IPO for pivotal immune-disease drug development
biospace
Sep 17, 26
DPHARM: How to address the clinical trial enrollment crisis?
fiercebiotech
Sep 16, 26
Gilead reaches HIV PrEP agreements; Hong Kong investigates Cloudbreak IPO
endpoints
Sep 15, 26
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
biopharma dive
Sep 14, 26
Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
fiercebiotech
Sep 13, 26
STAT+: Trump’s secretive pharma deals may undermine ‘most-favored nation’ pricing, an analysis suggests
stat
Sep 11, 26
STAT+: Pharma wins a battle over the cost of wastewater treatment in Europe
stat
Sep 11, 26
STAT+: Up and down the ladder: The latest comings and goings
stat
Sep 11, 26
STAT+: Pharmalittle: We’re reading about anxious Novartis investors, patent expirations for biologics, and more
stat
Sep 11, 26
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
biopharma dive
Sep 11, 26
BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
fiercebiotech
Sep 10, 26
Platinum-based chemotherapy in childhood causes mutations that age the liver
stat
Sep 10, 26
STAT+: The gifts from pharma companies that keep on giving
stat
Sep 10, 26
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
fiercebiotech
Sep 10, 26
STAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more
stat
Sep 10, 26
STAT+: Cancer medicines remain in short supply across the U.S., survey finds
stat
Sep 10, 26
Tyra shares slip as bladder cancer responses fall short of investor expectations
biospace
Sep 9, 26
CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’
fiercebiotech
Sep 9, 26
Compass posts positive psilocybin data; Solstice makes $225M debut
endpoints
Sep 9, 26
BMS clinches pivotal win for myeloma CAR T in ‘key derisking event’
biospace
Sep 4, 26
This week in charts: China deals, stock flatlines and Lilly’s M&A spree
biopharma dive
Sep 3, 26
The hidden scale-out problem behind CAR-T’s growth
biopharma dive
Sep 1, 26
ArsenalBio sheds most of staff in pivot to in vivo CAR-T
fiercebiotech
Aug 31, 26
Electra aims to light up Nasdaq with IPO for phase 2/3 I&I push
fiercebiotech
Aug 28, 26
Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
biopharma dive
Aug 28, 26
Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact
fiercebiotech
Aug 27, 26
Gilead gets another HIV treatment approval, extending lenacapavir's dominance
endpoints
← prev
page 3 of 7
next →
